Wave Life Sciences (WVE) filed an amendment to its 10-K report, providing detailed information on its directors, executive officers, corporate governa...
Wave Life Sciences (WVE) reported stronger-than-expected Q1 2026 results, with revenue up to US$38.25 million and a narrower net loss of US$26.09 mill...
Neutral
RBC Capital maintained an Outperform rating on Wave Life Sciences (WVE) but lowered its price target to $15 from $27, citing seasonal headwinds and br...